217 results
Page 4 of 11
8-K
4ke9u2ln2b5vwgywtjh
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
0x4syv mayf43
29 Nov 22
Business combination disclosure
4:03pm
8-K
ha9ow11so8gnp6 3x
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
6gi15zp4lw9ytpo
28 Nov 22
Business combination disclosure
4:03pm
8-K
i5rys2
28 Nov 22
Regulation FD Disclosure
4:01pm
425
f6txw
15 Nov 22
Business combination disclosure
4:03pm
8-K
qypxzxax
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
425
bh64g040ppcg9xbl9ov
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.2
sx4y249oi4g6u73
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
8-K
EX-99.1
rkzvwci swkmigw
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
8-K
s7go7i djpmlc
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
424B3
3y94xvrazebsl e9i
10 Nov 22
Prospectus supplement
4:21pm
425
bajxo fg6o
27 Oct 22
Business combination disclosure
7:15am
8-K
xxday0ct34pz6n0l
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am
425
4bwscmc v2wqwsvh428
26 Oct 22
Business combination disclosure
5:17pm
8-K
1yn9goir
26 Oct 22
Regulation FD Disclosure
5:14pm
8-K
EX-99.1
aim9fv 3lwn
26 Oct 22
Regulation FD Disclosure
5:14pm
425
rozej35oa lv7b52jhx
26 Oct 22
Business combination disclosure
5:10pm